• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • EC approves Merck’s Keytruda for metastatic squamous NSCLC pjavascript:void('body')harmaceutical-technology
    March 19, 2019
    Micrograph showing a non-small cell lung carcinoma. Credit: Librepath.The European Commission (EC) has approved Merck’s anti-PD-1 therapy Keytruda as a first-line treatment for adults with metastatic squamous non-small cell lung cancer (NSCLC).

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service